At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 55 enrolled
Drug / intervention
Noribogainedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Multiple Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ascending Doses of Noribogaine in Healthy Volunteers.
In Brief
A Phase 1 clinical trial evaluating Noribogaine for Pharmacokinetics. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This trial will be a randomised, double-blind, sequential-group, multiple-dose, placebo-controlled, dose escalation trial to characterise the pharmacokinetics (PK), pharmacodynamics (PD) and safety of noribogaine in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacokinetics
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
Enrollment StartJun 2024
First PostedJul 2024
Primary CompletionDec 2024
Study CompletionJan 2025
TodayJul 2026
First PostedJul 1, 2024
Enrollment StartJun 20, 2024
Primary CompletionDec 23, 2024
Study CompletionJan 13, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.0 years ago
Interventions
Noribogainedrug
Noribogaine capsules